Elastomeric Infusion Pumps Market Analysis

Source: https://www.fortunebusinessinsights.com/elastomeric-infusion-pumps-market-114758

Market Overview

The global elastomeric infusion pumps market is experiencing significant growth, driven by the rising prevalence of chronic diseases such as cardiovascular disorders, cancer, and diabetes. These portable, balloon-based drug delivery devices enable continuous and on-demand infusion for pain management, chemotherapy, antibacterial therapy, and other clinical applications. The study period spans 2021–2034, with 2025 as the base year.

Key Market Drivers

Rising Burden of Chronic Diseases The growing incidence of cancer and other chronic conditions is increasing the volume of drug delivery procedures across healthcare settings. According to the Health Care Cost Institute (2023), approximately 1.0 million people in the U.S. undergo chemotherapy annually. Cancer incidence data from the CDC indicates 1.9 million cases in the U.S., 0.6 million in Germany, and 0.5 million each in the U.K. and France. Additionally, the Heart Failure Society of America (HFSA) reports that around 6.7 million Americans over age 20 currently live with heart failure, with projections reaching 8.7 million by 2030.

Homecare Adoption Approximately 47% of patients in the U.S. prefer hospital-at-home care as an alternative to inpatient settings (News Medical, 2024), creating a favorable environment for portable elastomeric pump adoption.

Market Restraints

The high cost of elastomeric infusion pumps remains a notable barrier. For instance, a B. Braun Easypump ST/LT ranges from approximately USD 120–500, potentially limiting adoption in cost-sensitive healthcare environments and lower-income regions.

Market Segmentation

• By Type: The continuous rate segment held a considerable share in 2024, supported by ongoing product approvals. In April 2024, Baxter received FDA clearance for its Novum IQ large volume infusion pump with Dose IQ Safety Software.
• By Application: Chemotherapy led the application segment in 2024, backed by global cancer prevalence. Australia alone is estimated to diagnose approximately 169,000 new cancer cases annually (AIHW, 2024).
• By End User: Hospitals & ASCs dominated, aided by improved healthcare infrastructure and the presence of around 9,600 active ambulatory surgical centers in the U.S. (Definitive Healthcare, 2024).

Regional Outlook

• North America held the largest share in 2024, driven by high per capita healthcare expenditure (USD 14,750 in the U.S. per CMS, 2024), advanced infrastructure, and robust R&D activity.
• Europe is expected to register a considerable CAGR, supported by high chronic disease burden — over 5.8 million people live with diabetes in the U.K. alone (Diabetes UK, 2023) — and active product launches and acquisitions by key players.
• Asia Pacific is also anticipated to grow at a notable CAGR, fueled by an increasing number of regional manufacturers offering innovative elastomeric pump solutions.

Competitive Landscape

The market is semi-consolidated, with a handful of players commanding significant shares. Key companies include:

• Baxter (U.S.)
• B. Braun SE (Germany)
• Promecon GmbH (Germany)
• Progressive Medical, Inc. (U.S.)
• Terumo Corporation (Japan)
• Vygon (France)
• Leventon (Spain)
• Avanos Medical, Inc. (U.S.)

Recent Developments:

• January 2025: Progressive Medical launched its SMARTeZ elastomeric infusion pump for continuous/intermittent antibiotic, chemotherapy, and general infusion therapies.
• November 2024: Avanos Medical's ON-Q pump was approved for separate payment eligibility under the NOPAIN Act, enhancing its commercial reach.